Clinical AEs and DLTs during treatment of the SACRED trial participants who received hydroxyurea treatment for conditional TCD velocities
| . | Total . |
|---|---|
| Patient-years | 343 |
| AEs | 566 |
| Participants with AEs | 73 |
| Grade 2 | 388 |
| Grade 3 | 178 |
| Grade 4 | 0 |
| Rate per patient-year | 1.6 |
| Grade 3-4 rate per patient-year | 0.5 |
| SAEs | 37 |
| Participants with SAEs | 23 |
| Grade 2 | 1 |
| Grade 3 | 30 |
| Grade 4 | 5 |
| Grade 5 | 1 |
| SAE rate per patient-year | 0.1 |
| DLTs | 312 |
| Participants with DLTs | 57 |
| Anemia | 116 |
| Neutropenia | 17 |
| Reticulocytopenia | 177 |
| Thrombocytopenia | 2 |
| Total CBC | 2462 |
| CBC with DLT, n (%) | 243 (10) |
| . | Total . |
|---|---|
| Patient-years | 343 |
| AEs | 566 |
| Participants with AEs | 73 |
| Grade 2 | 388 |
| Grade 3 | 178 |
| Grade 4 | 0 |
| Rate per patient-year | 1.6 |
| Grade 3-4 rate per patient-year | 0.5 |
| SAEs | 37 |
| Participants with SAEs | 23 |
| Grade 2 | 1 |
| Grade 3 | 30 |
| Grade 4 | 5 |
| Grade 5 | 1 |
| SAE rate per patient-year | 0.1 |
| DLTs | 312 |
| Participants with DLTs | 57 |
| Anemia | 116 |
| Neutropenia | 17 |
| Reticulocytopenia | 177 |
| Thrombocytopenia | 2 |
| Total CBC | 2462 |
| CBC with DLT, n (%) | 243 (10) |
CBC, complete blood count; DLTs, dose-limiting toxicities.